Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 17Gastrointestinal 4Tumor-Agnostic 3Other solid neoplasm 3Head & Neck 3Gynecologic 2Dermatologic 2Sarcoma 1Plasma cell 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 2Recurrence 1Ovarian Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 108Carboplatin 96pembrolizumab 63Cisplatin 62Cyclophosphamide 44Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 24olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Alpelisib × Gynecologic × Clear all
NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting
500 enrolled
BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
118 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡